Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction : A randomized, placebo-controlled, double-blind study (RUSSLAN)

Simple item page
dc.contributor.authorMoiseyev, V. S.
dc.contributor.authorPõder, P.
dc.contributor.authorAndrejevs, N.
dc.contributor.authorRuda, M. Y.
dc.contributor.authorGolikov, A. P.
dc.contributor.authorLazebnik, L. B.
dc.contributor.authorKobalava, Z. D.
dc.contributor.authorLehtonen, L. A.
dc.contributor.authorLaine, T.
dc.contributor.authorNieminen, Markku S.
dc.contributor.authorLie, K. I.
dc.date.accessioned2021-10-01T12:45:01Z
dc.date.available2021-10-01T12:45:01Z
dc.date.issued2002-09
dc.description.abstractAims: To evaluate the safety and efficacy of levosimendan in patients with left ventricular failure complicating acute myocardial infarction. Methods and Results: Levosimendan at different doses (0·1-0·4 μg . kg-1 . min-1) or placebo were administered intravenously for 6 h to 504 patients in a randomised, placebo-controlled, double-blind study. The primary end-point was hypotension or myocardial ischaemia of clinical significance adjudicated by an independent Safety Committee. Secondary end-points included risk of death and worsening heart failure, symptoms of heart failure and all-cause mortality. The incidence of ischaemia and/or hypotension was similar in all treatment groups (P=0·319). A higher frequency of ischaemia and/or hypotension was only seen in the highest levosimendan dose group. Levosimendan-treated patients experienced lower risk of death and worsening heart failure than patients receiving placebo, during both the 6h infusion (2·0% vs 5·9%; P=0·033) and over 24 h (4·0% vs 8·8%; P=0·044). Mortality was lower with levosimendan compared with placebo at 14 days (11·7% vs 19·6%; hazard ratio 0·56 [95% CI 0·33-0·951; P=0·031) and the reduction was maintained at the 180-day retrospective follow-up (22·6% vs 31·4%; 0·67 [0·45-1·00], P=0·053). Conclusions: Levosimendan at doses 0·1-0·2 μg . kg-1 . min-1 did not induce hypotension or ischaemia and reduced the risk of worsening heart failure and death in patients with left ventricular failure complicating acute myocardial infarction.en
dc.description.statusPeer reviewed
dc.format.extent11
dc.format.extent173047
dc.identifier.citationMoiseyev, V S, Põder, P, Andrejevs, N, Ruda, M Y, Golikov, A P, Lazebnik, L B, Kobalava, Z D, Lehtonen, L A, Laine, T, Nieminen, M S & Lie, K I 2002, 'Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction : A randomized, placebo-controlled, double-blind study (RUSSLAN)', European Heart Journal, vol. 23, no. 18, pp. 1422-1432. https://doi.org/10.1053/euhj.2001.3158
dc.identifier.doi10.1053/euhj.2001.3158
dc.identifier.issn0195-668X
dc.identifier.urihttps://dspace.rsu.lv/jspui/handle/123456789/6487
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=0036764821&partnerID=8YFLogxK
dc.identifier.urlhttps://academic.oup.com/eurheartj/article/23/18/1422/490755
dc.identifier.urlhttps://academic.oup.com/eurheartj/article/23/18/1422/490755
dc.language.isoeng
dc.relation.ispartofEuropean Heart Journal
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectHypotension
dc.subjectIschaemia
dc.subjectLeft ventricular failure
dc.subjectLevosimendan
dc.subjectMortality
dc.subjectMyocardial infarction
dc.subject3.2 Clinical medicine
dc.subject1.1. Scientific article indexed in Web of Science and/or Scopus database
dc.subjectCardiology and Cardiovascular Medicine
dc.titleSafety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction : A randomized, placebo-controlled, double-blind study (RUSSLAN)en
dc.type/dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/article

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Safety.pdf
Size:
168.99 KB
Format:
Adobe Portable Document Format
Download

Collections

Research outputs from Pure / Zinātniskās darbības rezultāti no ZDIS Pure